Followers | 4055 |
Posts | 152075 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
![](https://investorshub.advfn.com/uicon/162645.png?cb=1681428050)
Friday, January 26, 2024 12:43:50 PM
Recent PCSA News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 12:00:21 PM
- Processa Pharmaceuticals Provides Product Pipeline and Financial Update • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri • GlobeNewswire Inc. • 08/19/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:15:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:34:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:31:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:28:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:12:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 12:00:21 PM
- Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer • GlobeNewswire Inc. • 07/30/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/22/2024 09:59:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 12:00:22 PM
- Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 06/11/2024 06:19:42 PM
- Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer • GlobeNewswire Inc. • 06/11/2024 12:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/29/2024 04:15:13 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/28/2024 08:49:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:13:45 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/21/2024 08:10:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:16:05 PM
- Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:15:00 PM
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 03/25/2024 12:15:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM